NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace announced the publication of 3-year results from its Post-Approval Study in Neurology, showing an 82% median seizure reduction in drug-resistant focal epilepsy among 324 patients. The company also presented 12- and 18-month data from its NAUTILUS trial at AAN 2026, demonstrating a 77% median reduction in generalized tonic-clonic seizures and significant safety improvements for idiopathic generalized epilepsy.
Key figures
- Drug Name
- RNS System
- Phase Of Trial
- Post-Approval Study / NAUTILUS trial
- Pas study centers
- 32
- Pas study patients
- 324
- Pas seizure reduction median
- 82%
- Nautilius injury events decline
- 30%
- Nautilius rescue medication reduction
- 44%
- Nautilius gtc seizure reduction median
- 77%
- Nautilius clinical global impression change
- 80%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.